|Slideshows|June 29, 2017

Psychiatric Questions, Queries, and Quarrels

Author(s)Cynthia M.A. Geppert, MD, PhD, MA, MPH, MSBE, DPS, MSJ

In psychiatry, hot debates abound if you just look around-and if this Special Report collection is any indication, the result is a balance of opinion and civility made richer by virtue of opposing views.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

ByGrace Thetford-Harvey, MD,Tessa Manning, MD

December 2nd 2025

Digital Apps for Substance Use Reduction: Discussion With InvestigatorJon-Patrick Allem, PhD

ByJon-Patrick Allem, PhD

November 27th 2025

New Drug Application Submitted for Centanafidine for Treatment of ADHD

ByJessica Walters

November 25th 2025

Interrelation of Hormones and Adult ADHD

ByJessica Walters,J.J. Sandra Kooij, MD, PhD

November 25th 2025

Tolerance to Stimulant Medications in the Treatment of Children With ADHD

ByJames M. Swanson, PhD,Anthony A. Grace, PhD

November 21st 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Psychiatric Questions, Queries, and Quarrels

Newsletter

Related Content

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

Digital Apps for Substance Use Reduction: Discussion With InvestigatorJon-Patrick Allem, PhD

New Drug Application Submitted for Centanafidine for Treatment of ADHD

Interrelation of Hormones and Adult ADHD

Tolerance to Stimulant Medications in the Treatment of Children With ADHD

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

What Happened to Psychopathology?

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

Catatonia Crisis: Navigating the IV Lorazepam Shortage